CN101990434B - 用于治疗沙粒病毒感染的抗病毒药物 - Google Patents
用于治疗沙粒病毒感染的抗病毒药物 Download PDFInfo
- Publication number
- CN101990434B CN101990434B CN200980102314XA CN200980102314A CN101990434B CN 101990434 B CN101990434 B CN 101990434B CN 200980102314X A CN200980102314X A CN 200980102314XA CN 200980102314 A CN200980102314 A CN 200980102314A CN 101990434 B CN101990434 B CN 101990434B
- Authority
- CN
- China
- Prior art keywords
- bisbenzimidazole
- bisbenzimidazole base
- base
- group
- replaces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
成分 | g/100.0mL | 终浓度 |
碳酸氢钠 | 0.5g | 0.5% |
盐水 | 适量加至100.OmL | 适量加至100% |
成分 | g/100.0mL | 终浓度 |
候选化合物 | 0.300g | 30.0mg/mL |
.05%碳酸氢钠/盐水储备液 | 适量加至10.0mL | 适量加至100% |
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US645708P | 2008-01-15 | 2008-01-15 | |
US61/006,457 | 2008-01-15 | ||
PCT/US2009/030919 WO2009123776A2 (en) | 2008-01-15 | 2009-01-14 | Antiviral drugs for treatment of arenavirus infection |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101990434A CN101990434A (zh) | 2011-03-23 |
CN101990434B true CN101990434B (zh) | 2013-07-31 |
Family
ID=41136068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980102314XA Expired - Fee Related CN101990434B (zh) | 2008-01-15 | 2009-01-14 | 用于治疗沙粒病毒感染的抗病毒药物 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8623347B2 (zh) |
EP (1) | EP2240023A4 (zh) |
JP (1) | JP5795714B2 (zh) |
KR (1) | KR20100113500A (zh) |
CN (1) | CN101990434B (zh) |
AP (1) | AP2010005308A0 (zh) |
AU (1) | AU2009232276B2 (zh) |
BR (1) | BRPI0905388A2 (zh) |
CA (1) | CA2712071A1 (zh) |
WO (1) | WO2009123776A2 (zh) |
ZA (1) | ZA201004193B (zh) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8642596B2 (en) | 2004-12-06 | 2014-02-04 | Siga Technologies, Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses |
US8410149B2 (en) | 2004-12-06 | 2013-04-02 | Siga Technologies Inc. | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US7994221B2 (en) | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
US8791110B2 (en) | 2006-02-01 | 2014-07-29 | Siga Technologies, Inc. | Anti-arenaviral compounds |
CA2640687A1 (en) | 2006-02-01 | 2007-10-25 | Siga Technologies, Inc. | Anti-arenaviral compounds |
AP2267A (en) | 2006-03-02 | 2011-08-02 | Siga Technologies Inc | Antiviral drugs for treatment of arenavirus infection. |
US7977365B2 (en) | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
US8871746B2 (en) | 2006-03-02 | 2014-10-28 | Kineta Four, LLC | Antiviral drugs for treatment of arenavirus infection |
AU2008256727A1 (en) | 2007-05-23 | 2008-12-04 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
CA2698075C (en) | 2007-08-27 | 2016-04-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
JP2015193572A (ja) * | 2014-03-31 | 2015-11-05 | 宇部興産株式会社 | パーフルオロアルキル基を含むビベンズイミダゾール化合物、およびその製造方法 |
WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
AR106595A1 (es) | 2015-11-06 | 2018-01-31 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
EP4006034A1 (en) | 2017-10-18 | 2022-06-01 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
MA53561A (fr) | 2018-09-05 | 2022-05-11 | Incyte Corp | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) |
RS65335B1 (sr) | 2018-10-05 | 2024-04-30 | Annapurna Bio Inc | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293377A1 (en) * | 2004-11-03 | 2006-12-28 | Shlomit Wizel | Amorphous and polymorphic forms of telmisartan sodium |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9104395D0 (en) * | 1991-03-01 | 1991-04-17 | Ici Plc | Compound,preparation and use for metal extraction |
US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
CA2572750A1 (en) * | 2003-09-10 | 2005-03-17 | Anil Koul | Heterobicyclic compounds as pharmaceutically active agents |
JP5390186B2 (ja) * | 2005-08-12 | 2014-01-15 | ユナイテッド ステイツ ガバメント アズ レプリゼンティッド バイ ザ セクレタリー オブ ザ ユナイテッド ステイツ アーミー アンド ザ ユーエス アーミー メディカル リサーチ アンド マティリ | 広い抗菌スペクトルを有する抗菌性化合物 |
AP2267A (en) * | 2006-03-02 | 2011-08-02 | Siga Technologies Inc | Antiviral drugs for treatment of arenavirus infection. |
US7977365B2 (en) * | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
GB0616359D0 (en) | 2006-08-16 | 2006-09-27 | Crysoptix Ltd | Organic compound,optical film and method of production thereof |
-
2009
- 2009-01-14 WO PCT/US2009/030919 patent/WO2009123776A2/en active Application Filing
- 2009-01-14 AU AU2009232276A patent/AU2009232276B2/en not_active Ceased
- 2009-01-14 AP AP2010005308A patent/AP2010005308A0/en unknown
- 2009-01-14 CN CN200980102314XA patent/CN101990434B/zh not_active Expired - Fee Related
- 2009-01-14 JP JP2010543205A patent/JP5795714B2/ja not_active Expired - Fee Related
- 2009-01-14 US US12/735,392 patent/US8623347B2/en not_active Expired - Fee Related
- 2009-01-14 BR BRPI0905388A patent/BRPI0905388A2/pt not_active IP Right Cessation
- 2009-01-14 KR KR1020107014573A patent/KR20100113500A/ko not_active Application Discontinuation
- 2009-01-14 CA CA2712071A patent/CA2712071A1/en not_active Abandoned
- 2009-01-14 EP EP09727680A patent/EP2240023A4/en not_active Withdrawn
-
2010
- 2010-06-11 ZA ZA2010/04193A patent/ZA201004193B/en unknown
-
2013
- 2013-11-27 US US14/091,723 patent/US20140100245A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060293377A1 (en) * | 2004-11-03 | 2006-12-28 | Shlomit Wizel | Amorphous and polymorphic forms of telmisartan sodium |
Non-Patent Citations (1)
Title |
---|
OZTEKIN ALGUL等.《Activity of Bisbenzimidazoles Derivatives to Staphylococcus epidermidis》.《Asian Journal of Chemistry》.2007,第19卷(第4期), * |
Also Published As
Publication number | Publication date |
---|---|
BRPI0905388A2 (pt) | 2015-10-13 |
CN101990434A (zh) | 2011-03-23 |
WO2009123776A2 (en) | 2009-10-08 |
EP2240023A2 (en) | 2010-10-20 |
EP2240023A4 (en) | 2010-12-29 |
AU2009232276B2 (en) | 2013-10-24 |
AU2009232276A1 (en) | 2009-10-08 |
US20110027227A1 (en) | 2011-02-03 |
US20140100245A1 (en) | 2014-04-10 |
US8623347B2 (en) | 2014-01-07 |
KR20100113500A (ko) | 2010-10-21 |
ZA201004193B (en) | 2011-04-28 |
JP5795714B2 (ja) | 2015-10-14 |
CA2712071A1 (en) | 2009-10-08 |
AP2010005308A0 (en) | 2010-06-30 |
WO2009123776A3 (en) | 2009-12-30 |
JP2011519346A (ja) | 2011-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101990434B (zh) | 用于治疗沙粒病毒感染的抗病毒药物 | |
CN101801189B (zh) | 用于治疗沙粒病毒感染的抗病毒药 | |
ES2395101T3 (es) | Medicamentos antivirales para tratamiento de infecciones por arenavirus | |
JP6429292B2 (ja) | Her2増幅性癌の処置のための方法 | |
JP6200903B2 (ja) | アレナウイルス感染症の治療のための抗ウイルス薬 | |
JP2019163274A (ja) | 移植片対宿主病を処置し予防する方法 | |
CN101743008A (zh) | 用于治疗或预防登革热感染的抗病毒药 | |
US8492434B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
JP2021116296A (ja) | コロナウイルス感染の治療におけるファビピラビルの使用 | |
US20150157634A1 (en) | Methods of treating and preventing alloantibody driven chronic graft versus host disease | |
WO2021143754A1 (zh) | 用于癌症治疗的组合及其应用 | |
US8871746B2 (en) | Antiviral drugs for treatment of arenavirus infection | |
US8791110B2 (en) | Anti-arenaviral compounds | |
AU2022389961A1 (en) | Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GINEITE FOURTH LLC Free format text: FORMER OWNER: SIGA TECHNOLOGIES INC Effective date: 20150203 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: American New York Patentee after: SIGA TECHNOLOGIES, Inc. Address before: oregon Patentee before: SIGA TECHNOLOGIES, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150203 Address after: Washington State Patentee after: Kineta Four, LLC Address before: American New York Patentee before: SIGA TECHNOLOGIES, Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130731 Termination date: 20170114 |
|
CF01 | Termination of patent right due to non-payment of annual fee |